NCT06086366 Presynaptic Imaging in Major Depressive Episodes After COVID-19
| NCT ID | NCT06086366 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Centre for Addiction and Mental Health |
| Condition | Long COVID |
| Study Type | OBSERVATIONAL |
| Enrollment | 90 participants |
| Start Date | 2023-08-22 |
| Primary Completion | 2028-09-10 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 90 participants in total. It began in 2023-08-22 with a primary completion date of 2028-09-10.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this observational study focuses on understanding and addressing a subset of persistent neuropsychiatric symptoms occurring within 3 months after mild to moderate COVID-19 infection (COVID-DNP). COVID-DNP encompasses major depressive episodes (MDE) with or without additional neuropsychiatric symptoms.
Eligibility Criteria
Inclusion Criteria: * New onset MDE within 3 months after mild or moderate COVID-19, with MDE verified by the research version SCID for DSM 5. See "Positive COVID-19 diagnosis" listed after inclusion/exclusion criteria for a description of how this is determined. * Age 18 to 75. * Good general physical health with no active medical conditions based on self-report (except migraine or PASC). Exclusion Criteria: * Use of antidepressants in the previous month (6 weeks for fluoxetine). * Use of stimulant medication affecting dopamine release in the previous month * Use of antipsychotics in the previous month * History of neurological disease (except migraine, and PASC) based on self-report * Use of medications or herbal products or natural health products with central nervous system effects in past 2 weeks based on self-report * Presence of cigarette smoking in the past two months, based on self-report * Lifetime diagnosis of severe Substance or Alcohol Use Disorder, or diagnosis of mild to moderate Substance or Alcohol Use Disorder in the past two years, based on self-report and verified by the Research Version of Structured Clinical Interview for Diagnostic and Statistical Manual-5 (SCID-5-RV) * Use of recreational drugs, including marijuana, in the past two months, based on self-report and verified by the Research Version of Structured Clinical Interview for Diagnostic and Statistical Manual-5 (SCID-5-RV) * Positive urine drug or cotinine screen at any timepoint during the study * History of psychotic symptoms secondary to schizophrenia, schizophreniform, bipolar disorder, or brief psychotic disorder prior to COVID-19, based on self-report and verified by the Research Version of Structured Clinical Interview for Diagnostic and Statistical Manual-5 (SCID-5-RV) * Currently pregnant, based on self-report or positive pregnancy test at any timepoint during the study, in females (in our PET Centre females up to 65 years of age are given a urine pregnancy test prior to every PET scan) * Breastfeeding (for females) * Current disorders of coagulation, blood or ongoing use of anticoagulant medication, based on self-report * Claustrophobia, based on self-report * Weight over 400lbs and height over 7ft (requirements for fitting in the scanners and hospital gowns) * Presence of metal implant, object or electrical devices that are contraindicated for MRI, based on self-report * Severe allergic reaction to alcohol
Contact & Investigator
Jeffrey Meyer, M.D., PhD
PRINCIPAL INVESTIGATOR
Centre for Addiction and Mental Health
Frequently Asked Questions
Who can join the NCT06086366 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 75 Years, studying Long COVID. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06086366 currently recruiting?
Yes, NCT06086366 is actively recruiting participants. Contact the research team at liuyuhan0830@gmail.com for enrollment information.
Where is the NCT06086366 trial being conducted?
This trial is being conducted at Toronto, Canada.
Who is sponsoring the NCT06086366 clinical trial?
NCT06086366 is sponsored by Centre for Addiction and Mental Health. The principal investigator is Jeffrey Meyer, M.D., PhD at Centre for Addiction and Mental Health. The trial plans to enroll 90 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.